NCT01055145

Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients

Comparison of the Effect Between Levofloxacin and Moxifloxacin on the Culture Conversion After 3 Months Treatment Among MDR-TB Patients; Prospective Multicenter Randomized Open Label Phase III Trial

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 182 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Fluoroquinolone is a one of the most important drugs for treatment of multidrug-resistant TB (MDR-TB). Among them, levofloxacin and moxifloxacin has been used most widely. However, there is no study to directly compare the efficacy of levofloxacin and moxifloxacin among MDR-TB patients. The investigators will compare the efficacy of levofloxacin and moxifloxacin through a prospective multicenter randomized open label phase III trial.

Conditions

• TB

Interventions

Type	Name	Description
DRUG	levofloxacin, moxifloxacin	Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months

Timeline

• Start date: 2010-03-01
• Primary completion: 2012-07-01
• Completion: 2012-10-01
• First posted: 2010-01-25
• Last updated: 2012-11-27

Locations

29 sites across 1 country: South Korea